US20030139435A1 - N-heterocyclic inhibitors of TNF-alpha expression - Google Patents

N-heterocyclic inhibitors of TNF-alpha expression Download PDF

Info

Publication number
US20030139435A1
US20030139435A1 US10/183,179 US18317902A US2003139435A1 US 20030139435 A1 US20030139435 A1 US 20030139435A1 US 18317902 A US18317902 A US 18317902A US 2003139435 A1 US2003139435 A1 US 2003139435A1
Authority
US
United States
Prior art keywords
alkyl
hydrogen
substituted
heterocyclyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/183,179
Other languages
English (en)
Inventor
Gulzar Ahmed
Axel Metzger
Ian Henderson
David Diller
James Wen
Stephen Wrobleski
Katerina Leftheris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Pharmacopeia LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/183,179 priority Critical patent/US20030139435A1/en
Assigned to PHARMACOPEIA, INC. reassignment PHARMACOPEIA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AHMED, GULZAR, DILLER, DAVID J., HENDERSON, IAN, METZGER, AXEL, WEN, JAMES
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEFTHERIS, KATERINA, WROBLESKI, STEPHEN T.
Publication of US20030139435A1 publication Critical patent/US20030139435A1/en
Priority to US11/485,075 priority patent/US7253174B2/en
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIU, CHUNJIAN
Priority to US11/778,219 priority patent/US8044040B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to N-heterocyclic compounds that are effective in blocking cytokine production, and in particular the expression of TNF-alpha (TNF- ⁇ ), via inhibition of p38 kinase.
  • Compounds of the present invention are useful in the treatment of inflammatory diseases such as, for example, rheumatoid arthritis.
  • cytokines such as IL-1 and TNF- ⁇ is implicated in a wide variety of inflammatory diseases, including rheumatoid arthritis (RA), psoriasis, multiple sclerosis, inflammatory bowel disease, endotoxin shock, osteoporosis, Alzheimer's disease and congestive heart failure, among others [Henry et al., Drugs Fut., 24:1345-1354 (1999); Salituro et al., Curr. Med. Chem., 6:807-823 (1999)].
  • cytokines such as, for example, monoclonal antibody to TNF- ⁇ (Enbrel) [Rankin et al., Br. J. Rheumatol., 34:334-342 (1995)], soluble TNF- ⁇ receptor-Fc fusion protein (Etanercept) [Moreland et al., Ann. Intern. Med., 130:478-486 (1999)] and or IL-1 receptor antagonist [Bresnihan et al., Arthritis Rheum., 41:2196-2204 (1998)], can provide effective treatment for chronic inflammatory diseases. As none of the current treatments for inflammatory diseases provide complete relief of symptoms, and as most current treatments are associated with various drawbacks such as side effects, improved methods for treating inflammatory diseases are desirable.
  • TNF- ⁇ is a protein whose synthesis occurs in many cell types in response to an external stimulus, such as, for example, a mitogen, an infectious organism, or trauma. Signaling from the cell surface to the nucleus proceeds via several intracellular mediators including kinases that catalyze phosphorylation of proteins downstream in the signaling cascade. Important mediators for the production of TNF- ⁇ cytokine are the mitogen-activated protein (MAP) kinases, and in particular, p38 kinase.
  • MAP mitogen-activated protein
  • p38 Kinases are activated in response to various stress stimuli, including, but not limited to, proinflammatory cytokines, endotoxin, ultraviolet light, and osmotic shock. Activation of p38 requires dual phosphorylation by upstream MAP kinase kinases (MKK3 and MKK6) on threonine and tyrosine within a Thr-Gly-Tyr motif, characteristic of p38 isozymes.
  • MKK3 and MKK6 upstream MAP kinase kinases
  • p38 kinases phosphorylate and activate the transcription factors, ATF-2, MAX, CHOP, and C/ERPb, suggesting a role of p38 kinases in gene regulation.
  • p38 kinases phosphorylate other protein kinases, such as MAPK activated protein kinase-2/3 (MAPKAP-K2/3, or MK2/3), and MAP-kinase-interacting kinase 1/2 (MNK1/2).
  • MAPK activated protein kinase-2/3 MAPK activated protein kinase-2/3
  • MNK1/2 MAP-kinase-interacting kinase 1/2
  • Small molecule inhibitors of p38 are expected to have several advantages over protein inhibitors of TNF- ⁇ or IL-1. p38 inhibitors not only block the production of TNF- ⁇ and IL-1, but also directly interfere with many of their secondary biological effects. In addition, small molecule inhibitors are unlikely to induce immune reaction in patients, and are believed active following oral administration.
  • the present invention provides novel compounds that are potent and selective inhibitors of p38 ⁇ and ⁇ , and as such, are also potent inhibitors of TNF- ⁇ expression in human cells.
  • Compounds of the present invention are useful in the treatment of p38- and TNF- ⁇ expression-mediated inflammatory and other disorders, including, but not limited to, bone resorption, graft vs.
  • Atherosclerosis atherosclerosis, arthritis, osteoarthritis, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease states, adult respiratory distress syndrome, asthma, chronic pulmonary inflammatory disease, cardiac reperfusion injury, renal reperfusion injury, thrombus, glomerulonephritis, Chron's disease, ulcerative colitis, inflammatory bowel disease, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease, congestive heart failure and cachexia.
  • the compounds of the present invention are effective as inhibitors of inappropriate p38 activity, especially iso forms ⁇ and ⁇ , and in turn, of cytokine production, and in particular, of cellular TNF-alpha (TNF- ⁇ ) expression. Accordingly, compounds of the invention are useful for the inhibition, prevention and suppression of various pathologies associated with such activity, such as, for example, inflammation, asthma, arthritis, atherosclerosis, multiple sclerosis, psoriasis, autoimmune diseases, Alzeheimers disease and congestive heart failure, among others.
  • the principles of the present invention provide a compound, including isomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof, represented by Formula (I):
  • one of W, Y and X is selected from ⁇ C—CN, ⁇ C—F, ⁇ C—NO 2 , ⁇ C—Br, ⁇ C—NH 2 , ⁇ C—NHC(O)CH 3 and ⁇ C—Cl;
  • V is —NR 5 —;
  • Z is halogen or —N(R 1 )(R 2 )
  • R 1 and R 2 are the same or different and are selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl or substituted heterocyclyl;
  • R 5 is hydrogen or alkyl
  • R 6 is
  • R 7 is hydrogen, alkyl, substituted alkyl, alkoxy, or halogen
  • R 8 is hydrogen, alkyl, alkyloxy or cyano
  • R 9 is —C(O)R 10 or unsubstituted or substituted heterocyclyl
  • R 10 is —N(R 31 )(R 32 );
  • R 31 and R 32 are the same or different and are selected from hydrogen, alkyl, substituted alkyl, alkoxy, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl or substituted heterocyclyl;
  • R 11 is hydrogen, halogen, O—R 35 or —N(R 12 )(R 13 );
  • R 12 is hydrogen, alkyl, or substituted alkyl
  • R 13 is —(CH 2 ) m R 14 ;
  • —N(R 12 )(R 13 ) taken together may form a heterocyclyl or substituted heterocyclyl;
  • m 0, 1, 2 or 3;
  • R 14 is hydrogen, alkyl, substituted alkyl, —C(O)N(R 31 )(R 32 ), —N(R 33 )C(O)R 34 , aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl or
  • R 15 is hydrogen, alkyl or substituted alkyl
  • R 16 is hydrogen or alkyl
  • R 33 is hydrogen, alkyl, or substituted alkyl
  • R 34 is alkyl, substituted alkyl, aryl or substituted aryl
  • R 35 is hydrogen or -(lower alkyl)-R 36
  • R 36 is N(R 37 )(R 38 )
  • R 37 is hydrogen, alkyl, or substituted alkyl
  • R 38 is -(substituted alkyl)-R 14 ;
  • N(R 37 )(R 38 ) taken together may form a heterocyclyl or substituted heterocyclyl.
  • Preferred compounds of this invention are those of Formula (I) including a pharmaceutically acceptable salt thereof
  • one or two of W, Y and X are ⁇ N—;
  • one of W, Y and X is selected from ⁇ C—CN, ⁇ C—F, ⁇ C—NO 2 , ⁇ C—Br, ⁇ C—NH 2 , ⁇ C—NHC(O)CH 3 and ⁇ C—Cl;
  • V is —NH—
  • Z is —N(R 1 )(R 2 );
  • R 1 and R 2 are the same or different and are selected from hydrogen, alkyl or substituted alkyl wherein alkyl is of 1 to 8 carbons;
  • R 7 is hydrogen, alkyl of 1 to 4 carbons, alkoxy of 1 to 4 carbons, or halogen;
  • R 8 is hydrogen
  • R 9 is —C(O)R 10 or unsubstituted or substituted heterocyclyl
  • R 10 is —NH 2 or unsubstituted or substituted —NH-alkyl, —NH-alkoxy, —NH-heterocyclyl, —NH-phenyl, or —NH—CH 2 -phenyl wherein alkyl and alkoxy are of 1 to 6 carbons;
  • R 11 is hydrogen, halogen, O—R 35 or —N(R 12 )(R 13 ), wherein N(R 12 )(R 13 ) taken together may form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2, or 3 additional nitrogen atoms or wherein
  • R 12 is hydrogen
  • R 13 is alkyl of 1 to 4 carbons or
  • R 15 and R 16 are independently selected from hydrogen and methyl
  • R 35 is hydrogen or -(lower alkyl)-R 36 ;
  • R 36 is N(R 37 )(R 38 )
  • R 37 is hydrogen, alkyl, or substituted alkyl
  • R 38 is -(substituted alkyl)-R 14 ;
  • N(R 37 )(R 38 ) taken together may form a heterocyclyl or substituted heterocyclyl.
  • the principles of the present invention also provide methods of inhibiting TNF- ⁇ expression in a mammal, wherein the methods comprise administering to the mammal an effective amount of a compound represented by Formula (I), or a prodrug or salt thereof.
  • inhibiting TNF- ⁇ expression is intended to include inhibiting, suppressing and preventing conditions associated with inappropriate TNF- ⁇ expression, including, but not limited to, inflammation, asthma, arthritis, atherosclerosis, multiple sclerosis, psoriasis, autoimmune diseases, Alzheimer's disease and congestive heart failure.
  • the principles of the present invention further provide methods of treating p38 kinase and TNF- ⁇ mediated disorders in a mammal, the methods comprising administering to a mammal in need of such treatment, an effective amount of a compound represented by Formula (I), or a prodrug or salt thereof.
  • a p38 kinase mediated disorder means a disorder associated with inappropriate p38 kinase activity
  • a TNF- ⁇ mediated disorder means a disorder associated with inappropriate TNF- ⁇ expression.
  • disorders include, but are not limited to, inflammation, asthma, arthritis, atherosclerosis, multiple sclerosis, psoriasis, autoimmune diseases, Alzheimer ⁇ s disease and congestive heart failure.
  • the compounds of the invention may be used in the manufacture of a pharmaceutical composition or medicament for the prophylactic or therapeutic treatment of disease states in mammals.
  • the compounds of the present invention may be administered as pharmaceutical compositions as a monotherapy, or in combination with, for example, other anti-inflammatory, e.g. a steroid or NSAID (non-steroidal anti-inflammatory drug) and/or immunosuppressive agents.
  • a steroid or NSAID non-steroidal anti-inflammatory drug
  • immunosuppressive agents can involve the administration of the various pharmaceuticals as a single dosage form or as multiple dosage forms administered simultaneously or sequentially.
  • Suitable routes of administration may be employed for providing a patient with an effective amount of a compound of the present invention.
  • Suitable routes of administration may include, for example, oral, rectal, nasal, buccal, parenteral (such as, intravenous, intrathecal, subcutaneous, intramuscular, intrasternal, intrahepatic, intralesional, intracranial, intra-articular, and intra-synovial), transdermal (such as, for example, patches), and the like.
  • parenteral such as, intravenous, intrathecal, subcutaneous, intramuscular, intrasternal, intrahepatic, intralesional, intracranial, intra-articular, and intra-synovial
  • transdermal such as, for example, patches
  • oral dosage forms such as, for example, tablets, troches, dispersions, suspensions, solutions, capsules, soft gelatin capsules, and the like, may be preferred.
  • Administration may also be by controlled or sustained release means and delivery devices. Methods for the preparation of such dosage forms are well known in
  • compositions incorporating compounds of the present invention may include excipients, a pharmaceutically acceptable carrier, in addition to other therapeutic ingredients.
  • Excipients such as starches, sugars, microcrystalline cellulose, diluents, lubricants, binders, coloring agents, flavoring agents, granulating agents, disintegrating agents, and the like may be appropriate depending upon the route of administration. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.
  • the compounds of the present invention may be used in the form of pharmaceutically acceptable salts derived from inorganic or organic bases, and hydrates thereof. Included among such base salts are ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • the present invention provides a novel compound of Formula (I) including isomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof, comprising:
  • one or two of W, Y and X are ⁇ N—;
  • one of W, Y and X is selected from ⁇ C—CN, ⁇ C—F, ⁇ C—NO 2 , ⁇ C—Br, ⁇ C—NH 2 , ⁇ C—NHC(O)CH 3 and ⁇ C—Cl;
  • V is —NR 5 —;
  • Z is halogen or —N(R 1 )(R 2 );
  • R 1 and R 2 are the same or different and are selected from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl or substituted heterocyclyl;
  • R 5 is hydrogen or alkyl
  • R 7 is hydrogen, alkyl, substituted alkyl, alkoxy, or halogen
  • R 8 is hydrogen, alkyl, alkyloxy or cyano
  • R 9 is —C(O)R 10 or unsubstituted or substituted heterocyclyl
  • R 10 is —N(R 31 )(R 32 )
  • R 31 and R 32 are the same or different and are selected from hydrogen, alkyl, substituted alkyl, alkoxy, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl or substituted heterocyclyl;
  • R 11 is hydrogen, halogen, O—R 35 or —N(R 12 )(R 13 );
  • R 12 is hydrogen, alkyl, or substituted alkyl
  • R 13 is —(CH 2 ) m R 14 ;
  • —N(R 12 )(R 13 ) taken together may form a heterocyclyl or substituted heterocyclyl;
  • m 0, 1, 2 or 3;
  • R 14 is hydrogen, alkyl, substituted alkyl, —C(O)N(R 31 )(R 32 ), —N(R 33 )C(O)R 34 , aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl or
  • R 15 is hydrogen, alkyl or substituted alkyl
  • R 16 is hydrogen or alkyl
  • R 33 is hydrogen, alkyl, or substituted alkyl
  • R 34 is alkyl, substituted alkyl, aryl or substituted aryl
  • R 35 is hydrogen or -(lower alkyl)-R 36 ;
  • R 36 is N(R 37 )(R 38 );
  • R 37 is hydrogen, alkyl, or substituted alkyl
  • R 38 is -(substituted alkyl)-R 14 ;
  • N(R 37 )(R 38 ) taken together may form a heterocyclyl or substituted heterocyclyl.
  • the present invention provides a compound of Formula (I) including isomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof,
  • one or two of W, Y and X are ⁇ N—;
  • one of W, Y and X is selected from ⁇ C—CN, ⁇ C—F, ⁇ C—
  • V is —NH—
  • Z is —N(R 1 )(R 2 );
  • R 1 and R 2 are the same or different and are selected from hydrogen, alkyl or substituted alkyl wherein alkyl is of 1 to 8 carbons;
  • R 7 is hydrogen, alkyl of 1 to 4 carbons, alkoxy of 1 to 4 carbons, or halogen;
  • R 8 is hydrogen
  • R 9 is —C(O)R 10 or unsubstituted or substituted heterocyclyl
  • R 10 is —NH 2 or unsubstituted or substituted —NH-alkyl, —NH-alkoxy, —NH-heterocyclyl, —NH-phenyl, or —NH—CH 2 -phenyl wherein alkyl and alkoxy are of 1 to 6 carbons;
  • R 11 is hydrogen, halogen, O—R 35 or —N(R 12 )(R 13 ), wherein N(R 12 )(R 13 ) taken together may form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2, or 3 additional nitrogen atoms or wherein
  • R 12 is hydrogen
  • R 13 is alkyl of 1 to 4 carbons or
  • R 15 and R 16 are independently selected from hydrogen and methyl
  • R 35 is hydrogen or -(lower alkyl)-R 36 ;
  • R 36 is N(R 37 )(R 38 )
  • R 37 is hydrogen, alkyl, or substituted alkyl
  • R 38 is -(substituted alkyl)-R 14 ;
  • N(R 37 )(R 38 ) taken together may form a heterocyclyl or substituted heterocyclyl.
  • the present invention provides a compound of Formula (I) including isomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof,
  • one or two of W, Y and X are ⁇ N—;
  • one of W, Y and X is selected from ⁇ C—CN, ⁇ C—F, ⁇ C—NO 2 , ⁇ C—Br, ⁇ C—NH 2 , ⁇ C—NHC(O)CH 3 and ⁇ C—Cl;
  • V is —NH—
  • Z is —N(R 1 )(R 2 )
  • R 1 and R 2 are the same or different and are selected from hydrogen or alkyl of 1 to 8 carbons;
  • R 6 is
  • R 7 is hydrogen, methyl, methoxy, Cl, Br, or F;
  • R 8 is hydrogen
  • R 9 is —C(O)R 10 or unsubstituted or substituted heterocyclyl
  • R 10 is —NH 2 , or unsubstituted or substituted —NH-alkyl, —NH-alkoxy, —NH-phenyl, or —NH—CH 2 -phenyl wherein alkyl and alkoxy are of 1 to 6 carbons; and
  • R 11 is hydrogen, halogen, O—R 35 or —N(R 2 )(R 13 ), wherein N(R 12 )(R 13 ) taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2, or 3 additional nitrogen atoms.
  • the present invention provides a compound of Formula (I) including isomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof,
  • one of W, Y and X is ⁇ N—;
  • one of W, Y and X is selected from ⁇ C—CN, ⁇ C—F, ⁇ C—NO 2 , ⁇ C—Br, ⁇ C—NH 2 , ⁇ C—NHC(O)CH 3 and ⁇ C—Cl;
  • V is —NH—
  • Z is —N(R 1 )(R 2 );
  • R 1 and R 2 are the same or different and are selected from hydrogen or alkyl of 1 to 8 carbons;
  • R 7 is hydrogen, methyl, methoxy, Cl, Br, or F;
  • R 8 is hydrogen
  • R 9 is —C(O)R 10 or unsubstituted or substituted heterocyclyl
  • R 10 is —NH 2 , or unsubstituted or substituted —NH-alkyl, —NH-alkoxy, —NH-phenyl, or —NH—CH 2 -phenyl wherein alkyl and alkoxy are of 1 to 6 carbons;
  • R 11 is hydrogen, halogen, —O—R 35 or —N(R 12 )(R 13 ) wherein N(R 12 )(R 13 ) taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2, or 3 additional nitrogen atoms; and
  • R 15 and R 16 are independently selected from hydrogen and methyl.
  • the present invention provides a compound of Formula (I) including isomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof,
  • R 10 is —NH 2 , unsubstituted or substituted —NH—CH 3 , —NH—C 2 H 5 , —NH—OCH 3 , or —NH—OC 2 H 5 .
  • the present invention provides a compound of Formula (I) including isomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof,
  • R 9 is unsubstituted or substituted triazole, thiazole, oxadiazole or imidazole.
  • the present invention provides a compound of Formula (I) including isomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof,
  • R 11 is hydrogen, halogen, —O-(substituted alkyl), —NH-(substituted alkyl) or
  • the present invention provides a compound of Formula (I) including isomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof,
  • R 11 is hydrogen, halogen, —O-(substituted alkyl), —NH-(substituted alkyl) or
  • the present invention provides a compound of Formula (I) including isomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof,
  • the remaining W, Y or X is selected from ⁇ C—CN, ⁇ C—F, ⁇ C—NO 2 , ⁇ C—Br, ⁇ C—NH 2 , ⁇ C—NHC(O)CH 3 and ⁇ C—Cl;
  • V is —NH—
  • Z is —N(R 1 )(R 2 )
  • R 1 and R 2 are the same or different and are selected from hydrogen or alkyl of 1 to 8 carbons;
  • R 7 is hydrogen, methyl, methoxy, Cl, Br, or F;
  • R 8 is hydrogen
  • R 9 is —C(O)R 10 or unsubstituted or substituted heterocyclyl
  • R 10 is —NH 2 , or unsubstituted or substituted —NH-alkyl, —NH-alkoxy, —NH-phenyl, or —NH—CH 2 -phenyl wherein alkyl and alkoxy are of 1 to 6 carbons;
  • R 11 is hydrogen, halogen, —O—R or —N(R 12 )(R 13 ), wherein N(R 12 )(R 13 ) taken together may form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2, or 3 additional nitrogen atoms; and
  • R 15 and R 16 are independently selected from hydrogen and methyl.
  • the present invention provides a compound of Formula (I) including isomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof,
  • R 10 is —NH 2 , unsubstituted or substituted —NH—CH 3 , —NH—C 2 H 5 , —NH—OCH 3 , or —NH—OC 2 H 5 .
  • the present invention provides a compound of Formula (I) including isomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof,
  • R 9 is unsubstituted or substituted triazole, thiazole, oxadiazole or imidazole.
  • the present invention provides a compound of Formula (I) including isomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof,
  • R 11 is hydrogen, halogen, —O-(substituted alkyl), —NH-(substituted alkyl) or
  • the present invention provides a compound of Formula (I) including isomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof,
  • R 11 is hydrogen, halogen, —O-(substituted alkyl), —NH-(substituted alkyl) or
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising as an active ingredient, a compound of the invention or a prodrug or salt thereof, and a pharmaceutically acceptable carrier.
  • the present invention to provides a pharmaceutical composition further comprising one or more additional active ingredients.
  • the present invention provides a pharmaceutical composition wherein the additional active ingredient is an anti-inflammatory compound or an immunosuppressive agent.
  • the present invention provides a pharmaceutical composition wherein the additional active ingredient is chosen from a steroid and an NSAID.
  • the present invention provides a method of inhibiting TNF- ⁇ expression in a mammal comprising administering to the mammal an effective amount of the pharmaceutical composition of the invention.
  • the present invention provides a method of treating TNF- ⁇ mediated disorder comprising administering to a mammal in need of such treatment, an effective amount of a pharmaceutical composition of the invention.
  • the present invention provides a method of treating TNF- ⁇ mediated disorder, wherein the TNF- ⁇ mediated disorder is an inflammatory disorder.
  • the present invention provides a method of treating TNF- ⁇ mediated disorder, wherein the TNF- ⁇ mediated disorder is chosen from bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthritis, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease states, adult respiratory distress syndrome, asthma, chronic pulmonary inflammatory disease, cardiac reperfusion injury, renal reperfusion injury, thrombus, glomerulonephritis, Chron's disease, ulcerative colitis, inflammatory bowel disease, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease, congestive heart failure and cachexia.
  • the TNF- ⁇ mediated disorder is chosen from bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthritis, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease states, adult respiratory distress syndrome, asthma, chronic pulmonary
  • the present invention provides a method of treating TNF- ⁇ mediated disorder wherein the pharmaceutical composition of the invention is administered with one or more additional anti-inflammatory or immunosuppressive agents as a single dose form or as separate dosage forms.
  • the present invention provides a method of treating a condition associated with TNF- ⁇ expression in a mammal comprising administering to a mammal in need of such treatment, an effective amount of a pharmaceutical composition of the invention.
  • the present invention provides a method of treating a condition associated with TNF- ⁇ expression in a mammal wherein the condition associated with TNF- ⁇ expression is an inflammatory disorder.
  • the present invention provides a method of treating a condition associated with TNF- ⁇ expression, wherein the condition associated with TNF- ⁇ expression is chosen from bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthritis, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease states, adult respiratory distress syndrome, asthma, chronic pulmonary inflammatory disease, cardiac reperfusion injury, renal reperfusion injury, thrombus, glomerulonephritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease, congestive heart failure and cachexia.
  • the condition associated with TNF- ⁇ expression is chosen from bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthritis, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease states, adult respiratory distress syndrome,
  • the present invention provides a method of treating a condition associated with TNF- ⁇ expression wherein the pharmaceutical composition of the invention is administered with one or more additional anti-inflammatory or immunosuppressive agents as a single dose form or as separate dosage forms.
  • the present invention provides a method of treating a condition associated with p38 kinase activity in a mammal comprising administering to a mammal in need of such treatment, an effective amount of a pharmaceutical composition of the invention.
  • the present invention provides a method of treating a condition associated with p38 kinase activity in a mammal wherein the condition associated with p38 activity is an inflammatory disorder.
  • the present invention provides a method of treating a condition associated with p38 kinase activity is chosen from bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthritis, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease states, adult respiratory distress syndrome, asthma, chronic pulmonary inflammatory disease, cardiac reperfusion injury, renal reperfusion injury, thrombus, glomerulonephritis, Chron's disease, ulcerative colitis, inflammatory bowel disease, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease, congestive heart failure and cachexia.
  • a condition associated with p38 kinase activity is chosen from bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthritis, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease states, adult respiratory distress syndrome, asthma, chronic
  • the present invention provides a method of treating a condition associated with p38 activity wherein the pharmaceutical composition of the invention is administered with one or more additional anti-inflammatory or immunosuppressive agents as a single dose form or as separate dosage forms.
  • the present invention provides a compound including isomers, enantiomers, diastereomers, tautomers, pharmaceutically acceptable salts, prodrugs and solvates selected from:
  • ATP adenosine triphosphate
  • EDTA ethylenediaminetetraacetic acid
  • MBP myelin basic protein
  • mRNA messenger RNA
  • PCR polymerase chain reaction
  • TBS t-butyldimethylsilyl
  • Alkyl is intended to include linear or branched hydrocarbon structures and combinations thereof of 1 to 20 carbons.
  • “Lower alkyl” means alkyl groups of from 1 to about 10, preferably from 1 to about 8, and more preferably, from 1 to about 6 carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, s-butyl, t-butyl, pentyl, iso-amyl, hexyl, octyl and the like.
  • Aryl means an aromatic hydrocarbon radical of 6 to about 16 carbon atoms, preferably of 6 to about 12 carbon atoms, and more preferably of 6 to about 10 carbon atoms.
  • Examples of aryl groups are phenyl, which is preferred, 1-naphthyl and 2-naphthyl.
  • Cycloalkyl refers to saturated hydrocarbon ring structures of from 3 to 12 carbon atoms, and preferably from 3 to 6 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, adamantyl, and the like. “Lower cycloalkyl”, refers to cycloalkyl of 3 to 6 carbons.
  • Heterocyclyl refers to saturated, partially saturated or unsaturated monocyclic structures of from 3 to 8 atoms, preferably 5 or 6 atoms, and bicyclic structures of 9 or 10 atoms containing one or more carbon atoms and from 1 to 4 heteroatoms chosen from O, N, and S. The point of attachment of the heterocyclyl structure is at an available carbon or nitrogen atom.
  • Examples include: imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole, pyrazole, pyrrolyl, pyridinyl, pyrazolyl, triazolyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, imidazolyl, indolyl, thiophenyl, furanyl, tetrazolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolindinyl, 1,3-dioxolanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazoly
  • Alkoxy means a straight, branched or cyclic hydrocarbon configuration and combinations thereof, including from 1 to 20 carbon atoms, preferably from 1 to 8 carbon atoms, more preferably from 1 to about 4 carbon atoms, and an oxygen atom at the point of attachment.
  • Suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, s-butoxy, t-butoxy, cyclopropyloxy, cyclohexyloxy, and the like.
  • “Lower alkoxy” refers to alkoxy groups having from 1 to 4 carbon atoms.
  • alkylthio refers to such groups having a sulfur atom at the point of attachment.
  • Alkenyl refers to an unsaturated acyclic hydrocarbon radical in so much as it contains at least one double bond. “Lower alkenyl” refers to such radicals containing from about 2 to about 10 carbon atoms, preferably from about 2 to about 8 carbon atoms and more preferably 2 to about 6 carbon atoms. Examples of suitable alkenyl radicals include propenyl, buten-1-yl, isobutenyl, penten-1-yl, 2-methylbuten-1-yl, 3-methylbuten-1-yl, hexen-1-yl, hepten-1-yl, and octen-1-yl, and the like.
  • Alkynyl refers to an unsaturated acyclic hydrocarbon radical containing at least one triple bond. Examples include ethynyl, propynyl, and the like.
  • Substituted alkyl means an alkyl wherein one or more hydrogens, preferably one, two, or three hydrogens, attached to an aliphotic carbon are replaced with a substituent such as —N(R 31 )(R 32 ), alkoxy, alkylthio, halogen, cyano, carboxyl, hydroxyl, —SO 2 -alkyl, —CO 2 -alkyl, —C(O)-alkyl, nitro, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, —C(O)—N(R 31 )(R 32 ), or —NH—C(O)-alkyl.
  • substituent groups include methoxy, ethoxy, propoxy, amino, methylamino, dimethylamino, phenyl naphthyl, chlorine, fluorine, and the like.
  • “Substituted cycloalkyl” means a cycloalkyl wherein one or more hydrogens, preferably one, two or three hydrogens, attached to a ring carbon are replaced with a substituent such as alkyl, substituted alkyl, —N(R 31 )(R 32 ), alkoxy, alkylthio, aryl, substituted aryl, halogen, cyano, carboxyl, hydroxyl, nitro, —SO 2 -alkyl, —CO 2 -alkyl, —C(O)-alkyl, —C(O)—N(R 3 )R 32 ), or —NH—C(O)-alkyl.
  • a substituent such as alkyl, substituted alkyl, —N(R 31 )(R 32 ), alkoxy, alkylthio, aryl, substituted aryl, halogen, cyano, carboxyl, hydroxyl, nitro, —SO 2
  • cycloalkyl rings having a fused aryl, preferably phenyl, or cycloalkyl such as
  • Substituted aryl means an aryl wherein one or more hydrogens, preferably one, two or three hydrogens, attached to an aromatic carbon are replaced with a substituent such as alkyl, substituted alkyl, —N(R 31 )(R 32 ) alkoxy, alkylthio, aryl, substituted aryl, halogen, cyano, nitro, carboxyl, hydroxyl, —SO 2 -alkyl, —CO 2 -alkyl, —C(O)-alkyl, —C(O)—N(R 3 )(R 32 ), or —NH—C(O)-alkyl.
  • a substituent such as alkyl, substituted alkyl, —N(R 31 )(R 32 ) alkoxy, alkylthio, aryl, substituted aryl, halogen, cyano, nitro, carboxyl, hydroxyl, —SO 2 -alkyl, —CO 2
  • substituents include methyl, isopropyl, methoxy, ethoxy, propoxy, amino, methylamino, dimethylamino, phenyl, chlorine, fluorine, —CO 2 CH 3 , —C(O)—NH 2 , and the like.
  • “Substituted heterocyclyl” means a heterocyclyl substituted at one or more available carbon or nitrogen atoms, preferably at one or two carbon and/or nitrogen atoms, with a substituent such as alkyl, substituted alkyl, —N(R 31 )(R 32 ), alkoxy, alkylthio, aryl, substituted aryl, halogen, cyano, nitro, oxo, carboxyl, hydroxyl, —SO 2 -alkyl, —CO 2 -alkyl, —C(O)-alkyl, —C(O)—N(R 31 )(R 32 ), or —NH—C(O)-alkyl.
  • substituent such as alkyl, substituted alkyl, —N(R 31 )(R 32 ), alkoxy, alkylthio, aryl, substituted aryl, halogen, cyano, nitro, oxo, carboxyl,
  • Halogen is intended to include for example, F, Cl, Br and I.
  • prodrug refers to a chemical compound that is converted to an active agent by metabolic processes in vivo. [See, e.g., N. Boder and J. J. Kaminski, Ann. Rep. Med. Chem. 22:303 (1987) and H. Bundgarrd, Adv. Drug Delivery Rev., 3:39 (1989)].
  • a prodrug of a compound of Formula I is intended to mean any compound that is converted to a compound of Formula I by metabolic processes in vivo.
  • the use of prodrugs of compounds of Formula I in any of the methods described herein is contemplated and is intended to be within the scope of the invention.
  • a protecting group refers to a group which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable.
  • the protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality. The removal or “deprotection” occurs after the completion of the reaction or reactions in which the functionality would interfere.
  • the typical functionalities that must be protected are amines. Suitable groups for that purpose are discussed in standard textbooks in the field of chemistry, such as Protective Groups in Organic Synthesis by T. W. Greene [John Wiley & Sons, New York, 1991], which is incorporated herein by reference. Particular attention is drawn to the chapter entitled “Protection for the Amino Group” (pages 309-405). Preferred protecting groups include BOC and Fmoc. Exemplary methods for protecting and deprotecting with these groups are found in Greene and Wuts on pages 318 and 327.
  • Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisometric forms which may be defined in terms of absolute stereochemistry as (R)— or (S)—, or as (D)— or (L)— for amino acids.
  • the present invention is meant to include all such possible diastereomers as well as their racemic and optically pure forms.
  • Optically active (R)— and (S)—, or (D)— and (L)— isomers may be prepared using chiral synthons or chiral reagents, or optically resolved using conventional techniques.
  • Compounds of the invention which incorporate chiral diamines may be resolved into pairs of enantiomers by known techniques. Where pure enantiomers of starting materials are not commercially available, they may be obtained by classic resolution, which may employ, for example, fractional crystallization of diastereomeric salts. Compounds of the invention may have more than one chiral center, for example wherein reductive amination of a homochiral intermediate leads to a mixture of diastereomers. Racemic intermediates and compounds of the invention may also be resolved by chromatographic separation, such as for example, HPLC using a column loaded with a homochiral support, to yield pure isomeric compounds.
  • any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration; thus a carbon-carbon double bond depicted arbitrarily herein as trans may be cis, trans, or a mixture of the two in any proportion.
  • the compounds of the present invention have demonstrated utility as selective inhibitors of inappropriate p38 kinase activity, and in particular, isoforms p38 ⁇ and p38 ⁇ .
  • compounds of the present invention have utility in the treatment of conditions associated with inappropriate p38 kinase activity.
  • Such conditions include diseases in which cytokine levels are modulated as a consequence of intracellular signaling via p38, and in particular, diseases that are associated with an overproduction of such cytokines as Il-1, Il-4, IL-8, and in particular, TNF- ⁇ .
  • compounds of the present invention are useful in the treatment and prevention of p-38 mediated conditions including, but not limited to, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, angiogenic disorders, infectious diseases, neurodegenerative diseases, viral diseases, allergies, myocardial ischemia, reperfusion/ischemia in stroke, heart attacks, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin-induced platelet aggregation, and conditions associated with prostaglandin endoperoxidase synthase-2.
  • Inflammatory diseases which may be treated or prevented include, but are not limited to, acute pancreatitis, chronic pancreatitis, asthma, allergies and adult respiratory distress syndrome.
  • Autoimmune diseases which may be treated or prevented include, but are not limited to, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosis, scleroderma, chronic thyroiditis, Grave ⁇ s disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, or graft vs. host disease.
  • Destructive bone disorders which may be treated or prevented include, but are not limited to, osteoporosis, osteoarthritis and multiple myeloma-related bone disorder.
  • Proliferative diseases which may be treated or prevented include, but are not limited to, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, and multiple myeloma.
  • Infectious diseases which may be treated or prevented include, but are not limited to, sepsis, septic shock, and Shigellosis.
  • Neurodegenerative diseases which may be treated or prevented by the compounds of this invention include, but are not limited to, Alzheimer's disease, Parkinson's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury.
  • Angiogenic disorders which may be treated or prevented include solid tumors, ocular neovasculization, infantile haemangiomas.
  • Viral diseases which may be treated or prevented include, but are not limited to, acute hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), HIV infection and CMV retinitis.
  • p38 inhibitors of this invention also exhibit inhibition of the expression of inducible pro-inflammatory proteins such as prostaglandin endoperoxide synthase-2 (PGHS-2), also referred to as cyclooxygenase-2 (COX-2).
  • PGHS-2 prostaglandin endoperoxide synthase-2
  • COX-2 cyclooxygenase-2
  • additional p38 mediated conditions include edema, analgesia, fever and pain, such as neuromuscular pain, headache, pain caused by cancer, dental pain and arthritis pain.
  • compounds of the present invention have utility in the treatment and prevention of diseases associated with cytokine production.
  • compounds of the present invention are useful in the treatment and prevention of:
  • Il-1 mediated diseases such as, for example, rheumatoid arthritis, osteoarthritis, stroke, endotoxemia and/or toxic shock syndrome, inflammatory reaction induced by endotoxin, inflammatory bowel disease, tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis, diabetes, pancreatic ⁇ -cell disease and Alzheimer's disease;
  • IL-8 mediated diseases or conditions such as, for example, those characterized by massive neutrophil infiltration, such as psoriasis, inflammatory bowel disease, asthma, cardiac and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulonephritis; and
  • TNF-mediated diseases or conditions such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis, bone resorption disease, reperfusion injury, graft vs.
  • viral infections such as HIV, CMV, influenza and herpes
  • veterinary viral infections such as lentivirus infections, including, but not limited to equine infectious anemia virus; or retro virus infections, including feline immunodeficiency virus, bovine immunodeficiency virus, or canine immunodeficiency virus.
  • the compounds of formula I including a pharmaceutically acceptable salt or hydrate thereof may be administered by any suitable route as described previously to treat the above mentioned diseases and conditions.
  • the method of administration will, of course, vary depending upon the type of disease being treated.
  • the amount of active compound administered will also vary according to the method of administration and the disease being treated.
  • An effective amount will be within the dosage range of about 0.1 to about 100 mg/kg, preferably about 0.2 to about 50 mg/kg, in a single or multiple doses administered at appropriate intervals throughout the day.
  • IC 50 values concentration required to inhibit 50% of specific binding
  • Preferred compounds have an IC 50 below 1 ⁇ M.
  • cDNAs of human p38 ⁇ , ⁇ and ⁇ isozymes were cloned by PCR. These cDNAs were subcloned in the pGEX expression vector (Pharmacia). GST-p38 fusion protein was expressed in E. Coli and purified from bacterial pellets by affinity chromatography using glutathione agarose. p38 fusion protein was activated by incubating with constitutively active MKK6. Active p38 was separated from MKK6 by affinity chromatography. Constitutively active MKK6 was generated according to Raingeaud et al. [ Mol. Cell. Biol., 1247-1255 (1996)].
  • PBMCs Peripheral blood mononuclear cells
  • assay medium RPMI medium containing 10% fetal bovine serum
  • 50 ⁇ l of cell suspension was incubated with 50 ⁇ l of test compound (4 ⁇ concentration in assay medium containing 0.2% DMSO) in 96 well-tissue culture plates for 5 minutes at room temperature.
  • 100 ⁇ l of LPS (200 ng/ml stock) was then added to the cell suspension and the plate was incubated for 6 hours at 37° C.
  • TNF ⁇ concentration in the medium was quantified using a standard ELISA kit (Pharmingen-San Diego, Calif.). Concentrations of TNF ⁇ and IC50 values for test compounds (concentration of compound that inhibited LPS-stimulated TNF ⁇ production by 50%) were calculated by linear regression analysis.
  • Human monocytic THP-1 cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum. Cells (40,000 cells in 80 ⁇ l) were added to wells of 96-well flat-bottomed plates. Tested compounds (10 ⁇ l) or vehicle (3% DMSO) were added to wells. Subsequently, LPS (Sigma, #L7261; 10 ⁇ l/well) was added to the cells for a final concentration of 1 ⁇ l/mL. Plates were incubated overnight at 37° C. and 5% CO 2 . Supernatant (50 ⁇ l/well) was harvested for an ELISA assay.
  • TNF was captured by an anti-human TNF antibody (R&D, #MAB610) which was pre-absorbed in high binding EIA plates (Costar, #3590). Captured TNF was recognized by a biotinlated anti-human TNF polyclonal antibody (R&D, #BAF210). Streptavidin conjugated with peroxidase was added to each well, and the activity of peroxidase was quantitated by a peroxide substrate kit (Pierce, #34062 and #34006).
  • the assays were performed in V-bottomed 96-well plates.
  • the final assay volume was 60 ⁇ l prepared from three 20 ⁇ l additions of enzyme, substrates (MBP and ATP) and test compounds in assay buffer (50 mM Tris pH 7.5, 10 mM MgCl 2 , 50 mM NaCl and 1 mM DTT).
  • assay buffer 50 mM Tris pH 7.5, 10 mM MgCl 2 , 50 mM NaCl and 1 mM DTT.
  • Bacterially expressed, activated p38 was pre-incubated with test compounds for 10 min. Prior to initiation of reaction with substrates. The reaction was incubated at 25° C. for 45 min. and terminated by adding 5 ⁇ l of 0.5 M EDTA to each sample.
  • the reaction mixture was aspirated onto a pre-wet filtermat using a Skatron Micro96 Cell Harvester (Skatron, Inc.), then wash with PBS.
  • the filtermat was then dried in a microwave oven for 1 min., treated with MeltilLex A scintillation wax (Wallac), and counted on a Microbeta scintillation counter Model 1450 (Wallac).
  • Inhibition data were analyzed by nonlinear least-squares regression using prizm (Graphpad Software).
  • the final concentration of reagents in the assays are ATP, 1 ⁇ M; [ ⁇ - 33 P]ATP, 3 nM,; MBP (Sigma, # M1891), 2 ⁇ g/well; p38, 10 nM; and DMSO, 0.3%.
  • compounds of Formula I wherein V is —NR 5 —; one or two of W, X and Y are N; and each of Z and R 11 are attached to the core pyrimidine or pyridine by —N— or —O—, may be prepared from trihalopyrimidine by sequential reactions with three different amines (1, 2, 3), or two different amines (1, 2) and an alcohol, and subsequent introduction of an additional substituent on the pyrimidine core.
  • An alternative method of preparation may start from dihalocyano-methylsulfanyl-pyrimidine (Scheme 2).
  • one of the amines will be an aniline and another will be a diamine suitably protected on its distal N.
  • the amines themselves, the sequence of the three substitutions, as well as the position of the nitrile may be varied, and are not limited by the particular example shown in Scheme 1 or Scheme 2.
  • Amine 1 corresponds to —N(R 5 )(R 6 ); Amine 2 corresponds to —Z; and Amine 3 corresponds to —R 11 and such designations are used interchangeably in the description below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
US10/183,179 2001-06-26 2002-06-26 N-heterocyclic inhibitors of TNF-alpha expression Abandoned US20030139435A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/183,179 US20030139435A1 (en) 2001-06-26 2002-06-26 N-heterocyclic inhibitors of TNF-alpha expression
US11/485,075 US7253174B2 (en) 2001-06-26 2006-07-12 N-heterocyclic inhibitors of TNF-α expression
US11/778,219 US8044040B2 (en) 2001-06-26 2007-07-16 N-heterocyclic inhibitors of TNF-alpha expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30102001P 2001-06-26 2001-06-26
US10/183,179 US20030139435A1 (en) 2001-06-26 2002-06-26 N-heterocyclic inhibitors of TNF-alpha expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/485,075 Continuation US7253174B2 (en) 2001-06-26 2006-07-12 N-heterocyclic inhibitors of TNF-α expression

Publications (1)

Publication Number Publication Date
US20030139435A1 true US20030139435A1 (en) 2003-07-24

Family

ID=23161582

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/183,179 Abandoned US20030139435A1 (en) 2001-06-26 2002-06-26 N-heterocyclic inhibitors of TNF-alpha expression
US11/485,075 Expired - Lifetime US7253174B2 (en) 2001-06-26 2006-07-12 N-heterocyclic inhibitors of TNF-α expression
US11/778,219 Expired - Fee Related US8044040B2 (en) 2001-06-26 2007-07-16 N-heterocyclic inhibitors of TNF-alpha expression

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/485,075 Expired - Lifetime US7253174B2 (en) 2001-06-26 2006-07-12 N-heterocyclic inhibitors of TNF-α expression
US11/778,219 Expired - Fee Related US8044040B2 (en) 2001-06-26 2007-07-16 N-heterocyclic inhibitors of TNF-alpha expression

Country Status (7)

Country Link
US (3) US20030139435A1 (enrdf_load_stackoverflow)
EP (1) EP1406875B1 (enrdf_load_stackoverflow)
JP (1) JP4510442B2 (enrdf_load_stackoverflow)
AU (1) AU2002316421B2 (enrdf_load_stackoverflow)
CA (1) CA2451128A1 (enrdf_load_stackoverflow)
HU (1) HUP0401711A3 (enrdf_load_stackoverflow)
WO (1) WO2003002544A1 (enrdf_load_stackoverflow)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082582A1 (en) * 2002-04-23 2004-04-29 Alaric Dyckman Pyrrolo-triazine aniline compounds useful as kinase inhibitors
US20040087601A1 (en) * 1999-07-15 2004-05-06 Erickson Shawn David Pyrimidine derivatives as IL-8 receptor antagonists
WO2004054505A3 (en) * 2002-12-12 2004-09-02 Pharmacia Corp Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
US20040229877A1 (en) * 2000-11-17 2004-11-18 Katerina Leftheris Methods of treating p38 kinase-associated conditions with pyrrolotriazine compounds
US20040248853A1 (en) * 2003-05-01 2004-12-09 Dyckman Alaric J. Pyrazole-amine compounds useful as kinase inhibitors
US20050107462A1 (en) * 2000-11-17 2005-05-19 Godfrey Jollie D.Jr. Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US6909001B2 (en) 2002-12-12 2005-06-21 Pharmacia Corporation Method of making tricyclic aminocyanopyridine compounds
US20050245530A1 (en) * 2004-04-23 2005-11-03 Borzilleri Robert M Monocyclic heterocycles as kinase inhibitors
US20060003967A1 (en) * 2004-06-30 2006-01-05 Zhongping Shi Method for preparing pyrrolotriazine compounds
US20060019928A1 (en) * 2004-06-30 2006-01-26 James Lin Tricyclic-heteroaryl compounds useful as kinase inhibitors
US20060030708A1 (en) * 2004-08-05 2006-02-09 Lobben Paul C Methods for the preparation of pyrrolotriazine compounds
US20060035891A1 (en) * 2004-05-18 2006-02-16 Hui Li Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20060063789A1 (en) * 2001-11-01 2006-03-23 Freyne Eddy Jean E Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors
US20060069110A1 (en) * 2004-09-27 2006-03-30 Andersen Denise L Substituted heterocyclic compounds and methods of use
US20060084644A1 (en) * 2004-09-23 2006-04-20 Manojit Pal Novel pyridine compounds, process for their preparation and compositions containing them
US7034151B2 (en) 2003-02-05 2006-04-25 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine kinase inhibitors
US7148348B2 (en) 2004-08-12 2006-12-12 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US20070179140A1 (en) * 2004-11-15 2007-08-02 Rigel Pharmaceuticals, Inc. Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds And Their Uses
US20070254896A1 (en) * 2006-03-23 2007-11-01 Jeannene Butler Substituted pyrimidine kinase inhibitors
US20070270425A1 (en) * 2005-12-21 2007-11-22 Guozhang Xu Substituted pyrimidinyl oxime kinase inhibitors
WO2007081630A3 (en) * 2005-12-21 2007-12-21 Janssen Pharmaceutica Nv Substituted pyrimidinyl kinase inhibitors
US7314876B2 (en) 2002-04-23 2008-01-01 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
US20080249304A1 (en) * 2005-12-21 2008-10-09 Hongfeng Chen Process for preparing substituted diaminopyrimidine oximes
US20100130486A1 (en) * 2007-07-17 2010-05-27 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
US8148391B2 (en) 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
WO2003002544A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2445208T3 (es) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
CN1717396A (zh) * 2002-11-28 2006-01-04 舍林股份公司 Chk－、Pdk－和Akt－抑制嘧啶,其制备及作为药物的用途
WO2004069829A1 (en) * 2003-01-10 2004-08-19 Pharmacopeia Drug Discovery, Inc. (2s)-2-((pyrimidin-4-yl)amino)-4-methylpentanoic acid aminoethylamid derivatives as il-8 receptor modulators for the treatment of atherosclerosis and rheumatoid arthritis
CN1835943B (zh) * 2003-01-14 2012-03-07 阿伦纳药品公司 作为代谢调节剂的1，2，3-三取代的芳基和杂芳基衍生物及其应用
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
EP1927594A1 (en) * 2003-01-14 2008-06-04 Arena Pharmaceuticals, Inc. 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
WO2005000298A2 (en) * 2003-06-03 2005-01-06 Novartis Ag 5-membered heterocycle-based p-38 inhibitors
WO2004113305A2 (en) 2003-06-16 2004-12-29 Vertex Pharmaceuticals Incorporated Diamino substituted quinazoline derivatives as promoters of smn2
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
RS53109B (en) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
BR122019017579B8 (pt) * 2003-08-15 2021-07-27 Novartis Ag 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
EP1687274A1 (en) * 2003-11-20 2006-08-09 Warner-Lambert Company LLC Androgen receptor modulators
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
WO2005121121A2 (en) * 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
ES2380550T3 (es) 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Compuestos de espiro-2,4-pirimidindiamina y sus usos
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20060247263A1 (en) * 2005-04-19 2006-11-02 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP2441757A1 (en) 2006-07-31 2012-04-18 Praecis Pharmaceuticals Incorporated Aurora kinase inhibitors from an encoded small molecule library
US8119798B2 (en) 2006-08-01 2012-02-21 Glaxosmithkline Llc P38 kinase inhibitors
EP2152702B1 (en) * 2007-05-04 2011-08-24 AstraZeneca AB Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer
PT2203173E (pt) 2007-10-26 2016-03-15 Academisch Ziekenhuis Leiden Resumo
LT2252300T (lt) * 2008-02-22 2017-02-10 Rigel Pharmaceuticals, Inc. 2,4-pirimidindiaminų panaudojimas aterosklerozės gydymui
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
WO2010077740A2 (en) * 2008-12-09 2010-07-08 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
AT509266B1 (de) * 2009-12-28 2014-07-15 Univ Wien Tech Substituierte pyridine und pyrimidine
US20120329784A1 (en) * 2010-01-13 2012-12-27 Kallander Lara S Compounds and methods
KR101531448B1 (ko) 2010-06-04 2015-06-24 에프. 호프만-라 로슈 아게 Lrrk2 조절제로서의 아미노피리미딘 유도체
PE20131371A1 (es) 2010-09-22 2013-11-25 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
EP3124483B1 (en) 2010-11-10 2019-07-10 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators
AU2013212758A1 (en) 2012-01-27 2014-08-14 Biomarin Technologies B.V. RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy
CN102952084A (zh) * 2012-11-15 2013-03-06 大连九信生物化工科技有限公司 一种4，6－二氯－2－甲硫基－5－硝基嘧啶的合成方法
KR20160095159A (ko) 2013-12-20 2016-08-10 시그날 파마소티칼 엘엘씨 치환된 디아미노피리미딜 화합물, 이의 조성물, 및 이를 사용한 치료방법
FI3242666T3 (fi) 2015-01-06 2024-12-16 Arena Pharm Inc Menetelmiä s1p1-reseptoriin liittyvien sairauksien hoitamiseksi
EP3310760B8 (en) 2015-06-22 2022-10-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
FI3442947T3 (fi) * 2016-04-15 2023-08-24 Epizyme Inc Amiinisubstituoituja aryyli- tai heteroaryyliyhdisteitä EHMT1- ja EHMT2-inhibiittoreina
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
US10689350B1 (en) * 2017-07-18 2020-06-23 Lonza Ltd Method for preparation of chlorinated s-propylthiobarbituric acid
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
SG11202003035SA (en) 2017-10-05 2020-04-29 Fulcrum Therapeutics Inc Use of p38 inhibitors to reduce expression of dux4
CN112601516A (zh) 2018-06-06 2021-04-02 艾尼纳制药公司 治疗与s1p1受体相关的病况的方法
PL3966207T3 (pl) 2019-05-10 2024-03-04 Deciphera Pharmaceuticals, Llc Fenyloaminopirymidynoamidowe inhibitory autofagii i sposoby ich zastosowania
CN120247875A (zh) 2019-05-10 2025-07-04 德西费拉制药有限责任公司 杂芳基氨基嘧啶酰胺自噬抑制剂及其使用方法
EP3983081A1 (en) 2019-06-17 2022-04-20 Deciphera Pharmaceuticals, LLC Aminopyrimidine amide autophagy inhibitors and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428044A (en) * 1989-05-20 1995-06-27 Fisons Plc Anti-inflammatory 4-aminophenyl derivatives
US6060591A (en) * 1996-12-10 2000-05-09 Dy Star Textilfarben Gmbh & Co. Deutschland K.G. Water-soluble fiber-reactive dyes, processes for their preparation, and their use
US6107301A (en) * 1993-10-12 2000-08-22 Dupont Pharmaceuticals Company 1N-alkyl-N-arylpyrimidinamines and derivatives thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6110563A (ja) * 1984-06-25 1986-01-18 Hokuriku Seiyaku Co Ltd ピリミジルアミノフエニルプロピオン酸誘導体
DE19715603A1 (de) * 1997-04-15 1998-10-22 Dystar Textilfarben Gmbh & Co Azofarbstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung
MY132496A (en) * 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
CZ2002846A3 (cs) * 1999-09-15 2003-02-12 Warner-Lambert Company Pteridinony, jako inhibitory kinasy
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
WO2001028561A1 (en) * 1999-10-21 2001-04-26 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
US20020065270A1 (en) * 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
ES2335265T3 (es) * 1999-12-28 2010-03-24 Pharmacopeia, Inc. Inhibidores de citoquina, especialmente de tnf-alfa.
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) * 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
EP1343782B1 (en) * 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
ATE420077T1 (de) 2001-05-29 2009-01-15 Bayer Schering Pharma Ag Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
WO2003002544A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
EP1453516A2 (de) * 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
DE50212771D1 (de) * 2001-10-17 2008-10-23 Boehringer Ingelheim Pharma Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428044A (en) * 1989-05-20 1995-06-27 Fisons Plc Anti-inflammatory 4-aminophenyl derivatives
US6107301A (en) * 1993-10-12 2000-08-22 Dupont Pharmaceuticals Company 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
US6342503B1 (en) * 1993-10-12 2002-01-29 Dupont Pharmaceuticals Company 1N-alkyl-n-arylpyrimidinamines and derivatives thereof
US6060591A (en) * 1996-12-10 2000-05-09 Dy Star Textilfarben Gmbh & Co. Deutschland K.G. Water-soluble fiber-reactive dyes, processes for their preparation, and their use

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087601A1 (en) * 1999-07-15 2004-05-06 Erickson Shawn David Pyrimidine derivatives as IL-8 receptor antagonists
US7037916B2 (en) 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
US7211666B2 (en) 2000-11-17 2007-05-01 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US20040229877A1 (en) * 2000-11-17 2004-11-18 Katerina Leftheris Methods of treating p38 kinase-associated conditions with pyrrolotriazine compounds
US20090227567A1 (en) * 2000-11-17 2009-09-10 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US20050107462A1 (en) * 2000-11-17 2005-05-19 Godfrey Jollie D.Jr. Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US20060063789A1 (en) * 2001-11-01 2006-03-23 Freyne Eddy Jean E Aminobenzamide derivatives as glycogen synthase kinase 3 beta inhibitors
US7759343B2 (en) 2002-04-23 2010-07-20 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
US20090105243A1 (en) * 2002-04-23 2009-04-23 Bristol-Myers Squibb Company Pyrrolo-Triazine Aniline Compounds Useful As Kinase Inhibitors
US7462616B2 (en) 2002-04-23 2008-12-09 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
US20040082582A1 (en) * 2002-04-23 2004-04-29 Alaric Dyckman Pyrrolo-triazine aniline compounds useful as kinase inhibitors
US7314876B2 (en) 2002-04-23 2008-01-01 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
US7160883B2 (en) 2002-04-23 2007-01-09 Bristol-Myers-Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
US6909001B2 (en) 2002-12-12 2005-06-21 Pharmacia Corporation Method of making tricyclic aminocyanopyridine compounds
WO2004054505A3 (en) * 2002-12-12 2004-09-02 Pharmacia Corp Method of using aminocyanopyridine compounds as mitogen activated protein kinase-activated protein kinase-2 inhibitors
US7034151B2 (en) 2003-02-05 2006-04-25 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine kinase inhibitors
US7390810B2 (en) 2003-05-01 2008-06-24 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
US20050004176A1 (en) * 2003-05-01 2005-01-06 Dyckman Alaric J. Pyrazole-amide compounds useful as kinase inhibitors
US20060247247A1 (en) * 2003-05-01 2006-11-02 Dyckman Alaric J Pyrazole-amine compounds useful as kinase inhibitors
US7414056B2 (en) 2003-05-01 2008-08-19 Bristol-Myers Squibb Company Pyrazole-amide compounds useful as kinase inhibitors
US7151113B2 (en) 2003-05-01 2006-12-19 Bristol Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
US20080004278A1 (en) * 2003-05-01 2008-01-03 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
US20040248853A1 (en) * 2003-05-01 2004-12-09 Dyckman Alaric J. Pyrazole-amine compounds useful as kinase inhibitors
US20080108626A1 (en) * 2003-05-01 2008-05-08 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
US7592338B2 (en) 2003-05-01 2009-09-22 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
US7253170B2 (en) 2003-05-01 2007-08-07 Bristol-Myers Squibb Company Pyrazole-amine compounds useful as kinase inhibitors
US7714138B2 (en) 2004-04-23 2010-05-11 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20050245530A1 (en) * 2004-04-23 2005-11-03 Borzilleri Robert M Monocyclic heterocycles as kinase inhibitors
US20090054436A1 (en) * 2004-04-23 2009-02-26 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20100183606A1 (en) * 2004-04-23 2010-07-22 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US7989477B2 (en) 2004-04-23 2011-08-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US7868013B2 (en) 2004-05-18 2011-01-11 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US7754714B2 (en) 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US9725419B2 (en) 2004-05-18 2017-08-08 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20080009494A1 (en) * 2004-05-18 2008-01-10 Rigel Pharmaceuticals, Inc. Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses
US8410093B2 (en) 2004-05-18 2013-04-02 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20110152518A1 (en) * 2004-05-18 2011-06-23 Rigel Pharmaceuticals, Inc. Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses
US7858633B2 (en) 2004-05-18 2010-12-28 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20060035891A1 (en) * 2004-05-18 2006-02-16 Hui Li Cycloalkyl substituted pyrimidinediamine compounds and their uses
US7534881B2 (en) 2004-06-30 2009-05-19 Bristol-Myers Squibb Company Method for preparing pyrrolotriazine compounds
US20060019928A1 (en) * 2004-06-30 2006-01-26 James Lin Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7253167B2 (en) 2004-06-30 2007-08-07 Bristol-Myers Squibb Company Tricyclic-heteroaryl compounds useful as kinase inhibitors
US20060003967A1 (en) * 2004-06-30 2006-01-05 Zhongping Shi Method for preparing pyrrolotriazine compounds
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US20060030708A1 (en) * 2004-08-05 2006-02-09 Lobben Paul C Methods for the preparation of pyrrolotriazine compounds
US7148348B2 (en) 2004-08-12 2006-12-12 Bristol-Myers Squibb Company Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US20060084644A1 (en) * 2004-09-23 2006-04-20 Manojit Pal Novel pyridine compounds, process for their preparation and compositions containing them
US7622486B2 (en) 2004-09-23 2009-11-24 Reddy Us Therapeutics, Inc. Pyridine compounds, process for their preparation and compositions containing them
US20060069110A1 (en) * 2004-09-27 2006-03-30 Andersen Denise L Substituted heterocyclic compounds and methods of use
US20070179140A1 (en) * 2004-11-15 2007-08-02 Rigel Pharmaceuticals, Inc. Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds And Their Uses
US8030483B2 (en) 2004-11-15 2011-10-04 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US20080051412A1 (en) * 2004-11-15 2008-02-28 Rigel Pharmaceuticals, Inc. Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds and their Uses
US8101627B2 (en) 2004-11-15 2012-01-24 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US7863286B2 (en) 2004-11-15 2011-01-04 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US8044054B2 (en) 2004-11-15 2011-10-25 Rigel Pharmaceuticals, Inc. Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
US20090176981A1 (en) * 2004-11-15 2009-07-09 Rigel Pharmaceuticals, Inc. Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds And Their Uses
US20090137589A1 (en) * 2004-11-15 2009-05-28 Rigel Pharmaceuticals, Inc. Stereoisomerically Enriched 3-Aminocarbonyl Bicycloheptene Pyrimidinediamine Compounds And Their Uses
US8153791B2 (en) 2005-12-21 2012-04-10 Janssen Pharmaceutica N.V. Substituted pyrimidinyl oxime kinase inhibitors
US20070270425A1 (en) * 2005-12-21 2007-11-22 Guozhang Xu Substituted pyrimidinyl oxime kinase inhibitors
WO2007081630A3 (en) * 2005-12-21 2007-12-21 Janssen Pharmaceutica Nv Substituted pyrimidinyl kinase inhibitors
US8278446B2 (en) 2005-12-21 2012-10-02 Janssen Pharmaceutica N.V. Process for preparing substituted diaminopyrimidine oximes
US8367825B2 (en) 2005-12-21 2013-02-05 Janssen Pharmaceutica N.V. Substituted pyrimidinyl oxime kinase inhibitors
US20080249304A1 (en) * 2005-12-21 2008-10-09 Hongfeng Chen Process for preparing substituted diaminopyrimidine oximes
US8013153B2 (en) 2006-03-23 2011-09-06 Janssen Pharmaceutica, N.V. Substituted pyrimidine kinase inhibitors
US20070254896A1 (en) * 2006-03-23 2007-11-01 Jeannene Butler Substituted pyrimidine kinase inhibitors
US8148391B2 (en) 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
US8552186B2 (en) 2006-10-23 2013-10-08 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors
US8993585B2 (en) 2007-07-17 2015-03-31 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors
US20100130486A1 (en) * 2007-07-17 2010-05-27 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors

Also Published As

Publication number Publication date
JP2004535447A (ja) 2004-11-25
AU2002316421B2 (en) 2008-05-15
HUP0401711A2 (hu) 2004-12-28
EP1406875A4 (en) 2005-05-04
US20060276488A1 (en) 2006-12-07
US8044040B2 (en) 2011-10-25
WO2003002544A1 (en) 2003-01-09
US7253174B2 (en) 2007-08-07
HUP0401711A3 (en) 2009-07-28
EP1406875B1 (en) 2013-07-31
US20080015185A1 (en) 2008-01-17
EP1406875A1 (en) 2004-04-14
CA2451128A1 (en) 2003-01-09
JP4510442B2 (ja) 2010-07-21

Similar Documents

Publication Publication Date Title
US7253174B2 (en) N-heterocyclic inhibitors of TNF-α expression
AU2002316421A1 (en) N-heterocyclic inhibitors of TNF-ALPHA expression
US6906067B2 (en) N-heterocyclic inhibitors of TNF-α expression
EP1242385B1 (en) Cytokine, especially tnf-alpha, inhibitors
US20020065270A1 (en) N-heterocyclic inhibitors of TNF-alpha expression
US20060069110A1 (en) Substituted heterocyclic compounds and methods of use
US20040023992A1 (en) Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
US20100125139A1 (en) Process for preparing quinazoline rho-kinase inhibitors and intermediates thereof
US20050250770A1 (en) Fused heterocyclic compounds
JP2007521278A (ja) ５員ヘテロ環を基礎とするｐ３８キナーゼ阻害剤
KR20160125527A (ko) 함질소 복소환 화합물 또는 그 염
CN1816529A (zh) 用作激酶抑制剂的芳基取代的吡唑－酰胺化合物
JP2006524645A (ja) Ｃｒｔｈ２によって媒介される病気の治療に有用なピリミジン誘導体
JP2007500129A (ja) ｐ−３８キナーゼ阻害剤
EP1409463B1 (en) N-heterocyclic inhibitors of tnf-alpha expression
US7037916B2 (en) Pyrimidine derivatives as IL-8 receptor antagonists
KR20050018947A (ko) 퀴나졸린 유도체
HUP0204168A2 (hu) Butin-diol-származékok, ilyeneket tartalmazó gyógyszerkészítmény és előállítása
Sova et al. Synthesis and biological evaluation of N-aryl-N’-(5-(2-hydroxybenzoyl) pyrimidin-2-yl) guanidines as toll-like receptor 4 antagonists
AU2002312590A1 (en) N-heterocyclic inhibitors of TNF-alpha expression

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHARMACOPEIA, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AHMED, GULZAR;METZGER, AXEL;HENDERSON, IAN;AND OTHERS;REEL/FRAME:013322/0301

Effective date: 20020912

Owner name: BRISTOL-MYERS SQUIBB COMPANY, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WROBLESKI, STEPHEN T.;LEFTHERIS, KATERINA;REEL/FRAME:013321/0875;SIGNING DATES FROM 20020817 TO 20020921

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: BRISTOL-MYERS SQUIBB COMPANY, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LIU, CHUNJIAN;REEL/FRAME:019225/0527

Effective date: 20060523